|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
AU2180500A
(en)
*
|
1998-12-15 |
2000-07-03 |
Warner-Lambert Company |
Use of a mek inhibitor for preventing transplant rejection
|
|
WO2000040237A1
(en)
*
|
1999-01-07 |
2000-07-13 |
Warner-Lambert Company |
Antiviral method using mek inhibitors
|
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
|
DE69926914T2
(de)
|
1999-01-13 |
2006-06-29 |
Warner-Lambert Co. Llc |
1-heterozyklus-substituierte diarylaminen
|
|
TR200102490T2
(tr)
*
|
1999-02-24 |
2001-12-21 |
F.Hoffmann-La Roche Ag |
Fenil ve piridinil türevleri
|
|
GB9910579D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
HUP0202381A3
(en)
*
|
1999-07-16 |
2004-12-28 |
Warner Lambert Co |
Method for treating chronic pain using mek inhibitors
|
|
KR20020012315A
(ko)
*
|
1999-07-16 |
2002-02-15 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
|
|
ES2208364T3
(es)
*
|
1999-07-16 |
2004-06-16 |
Warner-Lambert Company Llc |
Procedimiento para tratar dolor cronico usando inhibidores de mek.
|
|
ATE355836T1
(de)
*
|
2000-01-31 |
2007-03-15 |
Genaera Corp |
Inhibitoren der mucin-synthese
|
|
US7345051B2
(en)
|
2000-01-31 |
2008-03-18 |
Genaera Corporation |
Mucin synthesis inhibitors
|
|
GB0002740D0
(en)
*
|
2000-02-07 |
2000-03-29 |
Novartis Ag |
Organic compounds
|
|
EP1339702A1
(en)
|
2000-03-15 |
2003-09-03 |
Warner-Lambert Company |
5-amide substituted diarylamines as mek inhibitors
|
|
MXPA02008103A
(es)
*
|
2000-03-15 |
2002-11-29 |
Warner Lambert Co |
Diarilaminas sustituidas con 5-amida como inhibidores mek.
|
|
DE10017480A1
(de)
*
|
2000-04-07 |
2001-10-11 |
Transmit Technologietransfer |
Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
|
|
US6964982B2
(en)
|
2000-04-20 |
2005-11-15 |
Neurotech Co., Ltd. |
Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
|
|
JP3811775B2
(ja)
|
2000-07-19 |
2006-08-23 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
|
|
SK2072003A3
(en)
*
|
2000-08-25 |
2004-01-08 |
Warner Lambert Co |
Process for making N-aryl-anthranilic acids and their derivatives
|
|
EP1337513A1
(en)
|
2000-11-02 |
2003-08-27 |
AstraZeneca AB |
4-substituted quinolines as antitumor agents
|
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
|
IL149462A0
(en)
*
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
|
DOP2003000556A
(es)
*
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
|
CA2473545A1
(en)
|
2002-01-23 |
2003-07-31 |
Warner-Lambert Company Llc |
N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
KR100984595B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
|
|
US7012100B1
(en)
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
|
EP1551793B1
(en)
|
2002-06-19 |
2016-01-20 |
AmKor Pharma, Inc. |
Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
|
|
US7632866B2
(en)
|
2002-10-21 |
2009-12-15 |
Ramot At Tel Aviv University |
Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
|
|
WO2004035037A2
(en)
*
|
2002-10-21 |
2004-04-29 |
Ramot At Tel Aviv University Ltd. |
Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
|
|
WO2005000818A1
(en)
*
|
2003-06-27 |
2005-01-06 |
Warner-Lambert Company Llc |
5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
NZ546011A
(en)
|
2003-10-21 |
2009-09-25 |
Warner Lambert Co |
Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
CN1905873A
(zh)
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
NZ590160A
(en)
|
2003-11-21 |
2012-07-27 |
Array Biopharma Inc |
AKT protein kinase inhibitors
|
|
SE0401969D0
(sv)
*
|
2004-08-02 |
2004-08-02 |
Astrazeneca Ab |
Piperidine derivatives
|
|
ZA200703912B
(en)
*
|
2004-10-20 |
2008-09-25 |
Serono Lab |
3-arylamino pyridine derivatives
|
|
EP1838675A1
(en)
*
|
2004-11-24 |
2007-10-03 |
Laboratoires Serono S.A. |
Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
|
|
EP1828184B1
(en)
*
|
2004-12-01 |
2009-09-16 |
Merck Serono SA |
[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
|
|
ES2395952T3
(es)
|
2005-03-16 |
2013-02-18 |
Toyama Chemical Co., Ltd. |
Nuevo derivado del ácido antranílico o una sal del mismo
|
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
|
EP1883619B8
(en)
*
|
2005-05-25 |
2013-05-01 |
JW Pharmaceutical Corporation |
Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
|
|
AU2015255183C1
(en)
*
|
2005-10-07 |
2017-10-05 |
Exelixis, Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
AU2013203939B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
SI1934174T1
(sl)
*
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
AU2012261703B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
ATE523499T1
(de)
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CN101528231A
(zh)
*
|
2006-08-16 |
2009-09-09 |
埃克塞利希斯股份有限公司 |
在癌症的治疗中使用pi3k和mek调控剂
|
|
BRPI0717374A2
(pt)
|
2006-10-23 |
2013-10-29 |
Takeda Pharmaceutical |
Inibidores de mapk/erk quinase
|
|
PL2101759T3
(pl)
*
|
2006-12-14 |
2019-05-31 |
Exelixis Inc |
Sposoby stosowania inhibitorów MEK
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
WO2009037705A2
(en)
*
|
2007-09-20 |
2009-03-26 |
Ramot At Tel Aviv University Ltd. |
Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation
|
|
CN101868443A
(zh)
|
2007-09-20 |
2010-10-20 |
特拉维夫大学拉莫特有限公司 |
N-苯基邻氨基苯甲酸衍生物及其用途
|
|
KR100852962B1
(ko)
|
2007-11-12 |
2008-08-20 |
주식회사 뉴로테크 |
2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
|
|
EP2240455B1
(en)
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
ES2422733T3
(es)
|
2008-01-09 |
2013-09-13 |
Array Biopharma Inc |
Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
|
|
GB0813403D0
(en)
*
|
2008-07-22 |
2008-08-27 |
Lectus Therapeutics Ltd |
Potassium ion channel modulators & uses thereof
|
|
HRP20160044T1
(hr)
|
2008-08-04 |
2016-02-26 |
Merck Patent Gmbh |
Novi spojevi fenilamino izonikotinamida
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
EP2491014A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
ES2576061T3
(es)
|
2010-02-25 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
|
|
BR112012022801B8
(pt)
|
2010-03-09 |
2019-10-29 |
Dana Farber Cancer Inst Inc |
método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
RU2013148817A
(ru)
|
2011-04-01 |
2015-05-10 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и мек и способы их применения
|
|
WO2012135781A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
CN102617383A
(zh)
*
|
2012-03-20 |
2012-08-01 |
横店集团家园化工有限公司 |
索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
US9260393B2
(en)
*
|
2012-05-30 |
2016-02-16 |
Merck Patent Gmbh |
Solid state forms of N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
|
|
KR102204520B1
(ko)
*
|
2012-10-12 |
2021-01-20 |
엑셀리시스, 인코포레이티드 |
암의 치료에 사용하기 위한 화합물의 신규 제조 방법
|
|
CA2923835C
(en)
*
|
2013-09-11 |
2022-11-29 |
The Administrators Of The Tulane Educational Fund |
Novel anthranilic amides and the use thereof
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
CA3120351A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
WO2020106305A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
WO2020106308A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
WO2020106306A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
IL312977A
(en)
|
2021-11-23 |
2024-07-01 |
Nflection Therapeutics Inc |
Formulations of pyrrolopyridine-aniline compounds
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|